1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Ind-Swift Laboratories Ltd.

Ind-Swift Laboratories Ltd.

345.35
INR
+2.85
(+0.83%)
6.74EPS
29.45P/E
17.67BMarket Cap
Ind-Swift Laboratories Ltd.
NSE:INDSWFTLAB
(National Stock Exchange of India)

Recent

price

345.35

P/E

ratio

29.45

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
352.25
392.85
289.79
235.6
161.23
159.47
168.31
169.19
161.81
157.62
150.85
175.8
204.33
289.26
83.51
74.83
80.13
Revenue per Share
30.39
24.86
-30.07
-29.79
-29.14
-14.33
-9.2
4.88
6.19
-4.28
-0.53
-0.36
8.06
91.18
37.24
5.16
6.91
Basic EPS, GAAP
-55.92
-48.26
-25.74
8.44
14.44
10.71
14.91
11.52
-17.07
23.06
22.09
22.32
30.78
-44
-13.84
-18.64
- -
Free Cash Flow per Basic Share
0.95
0.95
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
168.92
217.09
217.32
177.05
145.14
126.31
118.76
121.26
123.57
108.42
102.14
101.71
115.41
137.44
193.5
159.38
- -
Book Value per Share
124.78
146.24
145.8
111.77
84.03
70.52
72.58
92.16
107.56
101.47
100.55
101.54
115.41
135.66
191.74
156.22
- -
Tangible Book Value per Share
29
36
39
41
41
41
43
45
47
49
59
59
59
59
67
84
83
Basic Weighted Avg Shares
10,370
14,092
11,361
9,651
6,605
6,532
7,162
7,625
7,566
7,796
8,913
10,387
12,073
17,091
5,617
6,259
6,647
Sales/Revenue/Turnover
13.71
10.5
1.82
0.21
3.85
5.11
4.82
8.11
5.89
9.38
12.45
8.9
15.04
14.19
-7.41
-0.77
4.23
Operating Margin (%)
409
399
544
658
843
847
883
866
1,040
901
873
1,310
574
804
245
306
315
Depreciation Expense
895
892
-1,179
-1,220
-1,194
-587
-391
220
289
-212
-31
-21
476
5,388
2,505
431
573
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
38.93
41.73
- -
117.48
117.15
44.72
9.86
2.82
15.23
19.67
Effective Tax Rate (%)
8.63
6.33
-10.38
-12.64
-18.07
-8.98
-5.46
2.88
3.83
-2.72
-0.35
-0.21
3.94
31.52
44.59
6.89
8.62
Profit Margin (%)
3,553
3,668
3,603
3,589
870
-1,454
-1,733
-976
4,801
5,400
6,297
7,409
7,934
5,265
6,448
7,195
- -
Working Capital
5,994
7,110
8,182
9,644
8,161
6,842
5,920
5,205
9,656
8,913
8,846
8,483
7,531
1,990
259
123
- -
LT Debt
5,781
8,237
8,534
7,252
5,945
5,174
5,313
5,490
5,878
6,406
6,034
6,009
6,819
8,121
11,730
13,840
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
2.32
4.76
- -
-1.18
-0.85
5.44
44.66
16.7
-1.08
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
2.44
5
- -
-1.19
-1.13
6.16
48.73
22.54
3.32
- -
Return on Capital (%)
17.43
12.72
-14.06
-15.46
-18.09
-10.56
-7.46
4.07
5.09
-3.45
-0.51
-0.36
7.42
72.12
25.24
3.37
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
56
- -
LT Borrowings
- -
121
- -
LT Finance Leases
- -
2
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
82
87
87
Market Capitalization
7,194
11,413
17,674

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
9,768
- -
Cash, Cash Equivalents & STI
- -
4,418
- -
Accounts Receivable, Net
- -
1,985
- -
Inventories
- -
1,479
- -
Total Current Liabilities
- -
2,573
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
56
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.08%
18.92%
17.99%
Free Cash Flow
-65.66%
-40.16%
67.45%
Net Income, GAAP
-186.7%
-290.19%
-82.78%
Sales/Revenue/Turnover
5.13%
3.73%
11.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
332
1,483
1,288
1,424
5,617
2026
1,583
1,526
1,509
1,698
6,259
2027
1,915
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.16
0.67
-0.82
33.04
37.24
2026
1.28
1
1.17
1.81
5.16
2027
2.84
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Ind-Swift Laboratories Limited manufactures active pharmaceutical ingredients, intermediates and formulations through group collaborations for global regulatory markets including the US, Europe and emerging regions. The company, founded in 1995 and headquartered in Chandigarh, India, specializes in APIs across therapeutic areas such as cardiovascular health including Atorvastatin Calcium and Ranolazine; antihistaminic; antidiabetic; antipsychotic including Aripiprazole; antimigraine; Parkinson's disease including Ropinirole HCl; antineoplastic including Letrozole and Anastrozole; ADHD symptoms; analgesics; alcohol abstinence; bone resorption inhibitors including Risedronate Sodium; and holds global leadership in macrolide antibiotics including Clarithromycin and its derivatives; it also provides contract research and manufacturing services with a 40,000 sq ft R&D center in Mohali, Punjab that has developed over 50 APIs and filed multiple DMFs. Facilities feature approvals from USFDA, EDQM, ANVISA, KFDA and others, supporting exports to regulated and row markets via six modern manufacturing sites. Recent developments include the sale of its API and CRAMS businesses to PI Industries via slump sale effective March 18, 2024; merger with Ind Swift Limited approved by NCLT and effective August 8, 2025 with appointed date March 31, 2024, involving allotment of preference shares and conversion of equity warrants; approval at June 2024 EGM for business expansion and investments up to INR 1,500 million in wholly owned subsidiaries by December 2027 including strategic greenfield and brownfield opportunities in India and abroad, plus INR 500 million in subsidiary loans or equity by December 2026; and strategic asset sales such as plant machinery to ANG Lifesciences for Rs 38.40 crores contributing to robust FY2025 profits of Rs 256 crores standalone.